Skip to main content

Feature Selection and Machine Learning Applied for Alzheimer’s Disease Classification

  • Conference paper
  • First Online:
VIII Latin American Conference on Biomedical Engineering and XLII National Conference on Biomedical Engineering (CLAIB 2019)

Abstract

Alzheimer disease (AD) is the most common type of dementia and one of the most serious mental health problems. Based on data analysis for classification of dementia, it is possible to distinguish the subjects into three groups: cognitively normal (CN), mild cognitive impairment (MCI) and AD. In this paper, the information of 628 patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.) database was used which contains 2163 features in order to select the most significant features that allows to the classification of CN vs. MCI/AD, the genetic package GALGO was applied to the features in which four features were selected and four classification techniques were used: Logistic Regression (LR), Random Forest (RF), Artificial Neural Networks (ANN) and Support Vector Machines (SVM). A cross validation of 70% training 30% test. According to the results, the technique with the most significant area under the curve (AUC) for the classification the subjects was LR presenting a value of 0.842.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Prince, M., et al.: World Alzheimer report 2015 the global impact of dementia an analysis of prevalence, incidence, cost and trends. Technical report, Alzeimer’s Disease International, United Kindom (2015). www.alz.co.uk/worldreport2015corrections

  2. Patterson, C.: World Alzheimer report 2018 - the state of the art of dementia research: new frontiers; World Alzheimer report 2018 - the state of the art of dementia research: New frontiers. Technical report, pp. 1–8. Alzheimer’s Disease International (ADI), London (2018). https://www.alz.co.uk/research/WorldAlzheimerReport2018.pdf

  3. Casanova, R., et al.: Alzheimer’s disease risk assessment using large- scale machine learning methods. PLoS One 8(11), e77949 (2013). https://doi.org/10.1371/journal.pone.0077949. Ed. by Stephen D Ginsberg

    Article  Google Scholar 

  4. Hinrichs, C., et al.: Predictive markers for AD in a multi-modality frame- work: an analysis of MCI progression in the ADNI population. Neuroimage 55, 574–589 (2011)

    Article  Google Scholar 

  5. Jo, T., Nho, K., Saykin, A.J.: Deep learning in Alzheimer’s disease: diagnostic classification and prognostic prediction using neuroimaging data. arXiv e-prints, May 2019. http://arxiv.org/abs/1905.00931

  6. R Core Team: The R Project for Statistical Computing (2019). https://www.r-project.org/

  7. Trevino, V., Falciani, F.: GALGO An R package for genetic algorithm searches (customized for variable selection in functional genomics). Technical report (2005). http://www.wag-inc.org

  8. Liaw, A., Wiener, M.: Classification and Regression by randomForest. Technical repot, vol. 3, pp. 18–22 (2002). https://www.r-project.org/doc/Rnews/Rnews2002-3.pdf

  9. Meyer, D.: Support vector machines * the interface to LIBSVM in pack- age e1071. Technical report, pp. 1–8. FH Technikum, Wien (2019). http://www.csie.ntu.edu.tw/~cjlin/papers/ijcnn.ps.gz

  10. Robin, X., et al.: pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 12(1), 77 (2011). https://doi.org/10.1186/1471-2105-12-77. https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-12-77

    Article  Google Scholar 

  11. ADNI - Alzheimer’s Disease Neuroimaging Initiative (2003). http://adni.loni.usc.edu/

  12. Honea, R.A., et al.: Impact of APOE on the healthy aging brain: a voxel- based MRI and DTI study. J. Alzheimers Dis. 18, 553–564 (2009)

    Article  Google Scholar 

Download references

Acknowledgments

Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Ana Gabriela Sánchez-Reyna .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this paper

Check for updates. Verify currency and authenticity via CrossMark

Cite this paper

Sánchez-Reyna, A.G. et al. (2020). Feature Selection and Machine Learning Applied for Alzheimer’s Disease Classification. In: González Díaz, C., et al. VIII Latin American Conference on Biomedical Engineering and XLII National Conference on Biomedical Engineering. CLAIB 2019. IFMBE Proceedings, vol 75. Springer, Cham. https://doi.org/10.1007/978-3-030-30648-9_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-30648-9_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-30647-2

  • Online ISBN: 978-3-030-30648-9

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics